[177Lu]Lu-PSMA-617 extends survival in mCRPC patients previously treated with ARPI, but its impact without prior taxane treatment was unclear until revealed at the ESCO Congress.

FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.

β-Inhibitors can inhibit the activity of β-lactamase inhibitors produced by drug-resistant bacteria. They are typically used in combination with β-lactam antibiotics to protect the β-lactam antibiotics from hydrolysis, thereby inhibiting enzyme-resistant bacteria.

This article summarized the latest R&D progress of Pilocarpine Hydrochloride, the mechanism of action for Pilocarpine Hydrochloride, and the drug target R&D trends for Pilocarpine Hydrochloride.

New data from the 2023 ASH conference is now available on the Clinical Results section of the Synapse database.

MoonLake Immunotherapeutics, a clinical-stage biotech firm, announced encouraging preliminary results from its global Phase 2 ARGO trial. This trial evaluated the efficacy and safety of Nanobody® sonelokimab in patients with active psoriatic arthritis.

The overexpression of BCL-2 protein allows tumor cells to evade apoptosis and to become resistant to a variety of anti-tumor drugs. Bcl-2 inhibitors are a new type of anti-cancer drug developed to target the mechanism of apoptosis, promoting cell death.

This article summarized the latest R&D progress of Perindopril Erbumine, the Mechanism of Action for Perindopril Erbumine, and the drug target R&D trends for Perindopril Erbumine.

At ASH 2023, results of SL-172154 as a single agent and with Azacitidine for relapsed/refractory AML and HR-MDS will be presented, highlighting its safety, pharmacodynamics, and anti-tumor effects.

Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.

ATR, a core DDR kinase, senses replication stress and signals S and G2/M checkpoints to initiate DNA repair. It's a hot target in anti-cancer drug development, with some ATR inhibitors already in clinical trials.

This article summarized the latest R&D progress of Pentostatin, the mechanism of action for Pentostatin, and the drug target R&D trends for Pentostatin.